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Abstract
Huntington’s disease (HD) is a neurodegenerative disorder characterized by unwanted choreatic movements, behavioral 
and psychiatric disturbances, and dementia. The activation of the hypoxic response pathway through the pharmacological 
inhibition of hypoxia-inducing factor (HIF) prolyl-hydroxylases (PHDs) is a promising approach for neurodegenerative 
diseases, including HD. Herein, we have studied the mechanism of action of the compound Betulinic acid hydroxamate 
(BAH), a hypoximimetic derivative of betulinic acid, and its efficacy against striatal neurodegeneration using complementary 
approaches. Firstly, we showed the molecular mechanisms through which BAH modifies the activity of the PHD2 prolyl 
hydroxylase, thus directly affecting HIF-1α stability. BAH treatment reduces PHD2 phosphorylation on Ser-125 residue, 
responsible for the control of its hydrolase activity. HIF activation by BAH is inhibited by okadaic acid and LB-100 indicat-
ing that a protein phosphatase 2A (PP2A) is implicated in the mechanism of action of BAH. Furthermore, in striatal cells 
bearing a mutated form of the huntingtin protein, BAH stabilized HIF-1α protein, induced Vegf and Bnip3 gene expression 
and protected against mitochondrial toxin-induced cytotoxicity. Pharmacokinetic analyses showed that BAH has a good 
brain penetrability and experiments performed in a mouse model of striatal neurodegeneration induced by 3-nitropropionic 
acid showed that BAH improved the clinical symptoms. In addition, BAH also prevented neuronal loss, decreased reactive 
astrogliosis and microglial activation, inhibited the upregulation of proinflammatory markers, and improved antioxidant 
defenses in the brain. Taken together, our results show BAH’s ability to activate the PP2A/PHD2/HIF pathway, which may 
have important implications in the treatment of HD and perhaps other neurodegenerative diseases.
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Introduction
Terpenoids and especially triterpenoids are the largest and 
the most diverse group of naturally occurring compounds. 
Some triterpenoids and their semi-synthetic derivatives 
can be identified as potential therapeutics against a wide 
number of diseases [1]. Betulinic acid (BA) is a lupane-
type triterpenoid having a special place among naturally 
derived remedies. Since botanical preparations containing 
BA as an active substance, it has been used in folk medi-
cine for centuries [2]. Several preclinical studies have shown 
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that BA is endowed with potent neuroprotective activities 
by targeting different pathways [3–8]. In addition, BA has 
been widely used to develop novel semi-synthetic deriva-
tives with improved pharmacological attributes [2, 9]. We 
have recently described that some triterpenoid hydroxa-
mate derivatives including betulinic acid hydroxamate 
(BAH) activate the hypoxia inducing factor (HIF) pathway 
and therefore represent promising small molecules for the 
development of new drug candidates against inflammatory 
diseases [10, 11].
HIF-1α and HIF-2α are transcription factors stabilized 
by a cellular low oxygen status (hypoxia). They regulate the 
expression of a host of genes whose products are involved 
in biological processes as diverse as erythropoiesis, angio-
genesis, vascular tone, and immunity. Molecular oxygen 
controls the cellular stability of HIF-1α and HIF-2α via 
HIF prolyl hydroxylases (PHDs), a class of iron-containing 
dioxygenases that, in the presence of molecular oxygen and 
2-oxoglutarate, hydroxylate HIF-1α and HIF-2α, inducing 
their ubiquitination by an E3-ubiquitin ligase and degrada-
tion by the 26S proteasome. Several lines of evidence suggest 
that the HIF-1α/HIF-2α stabilization induced by pharmaco-
logical inhibition of PHDs may be of clinical relevance for 
the treatment of ischemic and inflammatory conditions [12]. 
In addition, post-transcriptional modifications of PHD2 by 
dephosphorylation of Ser-125 have been described to inhibit 
its function and to stabilize HIF-1α protein [13]. Interest-
ingly, this dephosphorylation seems to be mediated by B55α 
(PPP2R2A), a subunit of the protein phosphatase 2A (PP2A) 
complex [13]. Moreover, it has been described recently that 
B55α/PP2A plays a major role in vascular remodeling [14], 
which is of special relevance for neuroinflammatory diseases 
where the blood brain barrier is compromised.
Huntington’s disease (HD) is a fatal autosomal dominant 
and progressive neurodegenerative disease caused by the 
expansion of a trinucleotide CAG repeat (> 36 glutamines) 
located 17 codons downstream of the initiation codon of 
the Huntingtin gene (Htt) [15]. Mutated Htt protein leads 
to death and dysfunction of the GABAergic medium spiny 
striatal neurons, leading to severe neurological symptoms 
that included chorea, cognitive impairment, and changes in 
mood and personality [16].
Hypoxia preconditioning induced by mild oxygen deple-
tion or by pharmacological inhibition of PHDs is expected to 
beneficially affect various neurological disorders including 
HD [17–20]. In this sense, HIF-1α protects against oxida-
tive stress by directly targeting mitochondria [21]. Indeed, 
mitochondrial energy metabolism is considered the primary 
defect in HD. Mitochondrial deficit tilts energy economy 
towards aerobic glycolysis to compensate the impaired oxi-
dative phosphorylation, and the upregulation of glycolytic 
enzymes by HIF-1α is a beneficial adaptive modification to 
cope with an overall impaired aerobic metabolism [16, 22].
An effort to discover small molecules inhibiting PHDs 
has led to big pharma and academic groups to develop PHDs 
inhibitors [23], with HD being a challenging additional phar-
maceutical target for this class of compounds [15]. Herein 
we investigated the mechanism of action of betulinic acid 
hydroxamate (BAH) to inhibit PHD2 activity and demon-
strated its efficacy in in vitro and in vivo models of HD.
Material and Methods
Cell Lines and Reagents
HEK-293T and NIH 3T3 cells were maintained at 37 °C 
in a humidified atmosphere containing 5% CO2 in DMEM 
supplemented with 10% fetal bovine serum (FBS), 2 mM 
L-glutamine, and 1% (v/v) penicillin/streptomycin. 
 STHdhQ7/Q7 and  STHdhQ111/Q111 cell lines, which express 
either a wild type or a mutated form of the huntingtin pro-
tein, were cultured at 33 °C and 5%  CO2 in DMEM sup-
plemented with 10% FBS, 2 mM L-glutamine, and 1% (v/v) 
penicillin/streptomycin [24]. HA-PHD1 (#18961), HA-
PHD2 (#18963), and HA-PHD3 (#18960) plasmids were 
obtained from Addgene. GST-PHD plasmids were provided 
by Edurne Berra (CICbioGUNE, Bilbao, Spain). All other 
reagents were purchased from Merk (St Louis, MO, USA). 
Scramble control oligonucleotide siRNA non-targeting 
pool (#D-001810) and ON-TARGET plus SMARTpool 
against B55α (#L-004824) were purchased from Dharma-
con (Waltham, MA, USA).
Western Blotting and Antibodies
After treatments, the cells were washed with PBS and 
proteins were extracted in 50 μl of lysis buffer (50 mM 
Tris–HCl pH 7.5, 150 mM NaCl, 10% glycerol, and 1% 
NP-40) supplemented with 10 mM NaF, 1 mM  Na3VO4, 
10 μg/ml leupeptine, 1 μg/ml pepstatin and aprotinin, and 
1 μl/ml PMSF saturated. Seventy micrograms of protein 
were boiled at 95 °C in Laemmli buffer and electrophoresed 
in 10% SDS/PAGE gels. Separated proteins were transferred 
to PVDF membranes (20 V for 30 min) and blocked in TBS 
solution containing 0.1% Tween 20 and 5% non-fat dry milk 
for 1 h at room temperature. Immunodetection of specific 
proteins was carried out by incubation with primary anti-
body against human HIF-1α (1:1000 dilution, #610,959, 
BD Biosciences, San Jose, CA, USA), murine HIF-1α 
(1:1000 dilution, #ab179483, Abcam, Cambridge, UK), 
PHD1 (1:1000 dilution, #ab108980, Abcam), PHD2 (1:1000 
dilution, #ab109088, Abcam), PHD3 (1:1000 dilution, 
#ab30782, Abcam), OH-HIF-1α (1:1000 dilution, #3434S, 
Cell Signaling, Danvers, MA, USA), B55α (1:1000 dilution, 
#5689S, Cell Signaling), anti-HA (1:1000 dilution, clone 
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3F10 Roche), anti-Phospho-PHD2 Ser-125 (1:500) [13], and 
β-actin (1:10.000 dilution, #A5316, Merk, St Louis, MO, 
USA) overnight at 4 °C. After washing membranes, horse-
radish peroxidase-conjugated secondary antibody was added 
and detected by chemiluminescence system (GE Healthcare 
Europe GmbH).
Cell Transfections and Immunoprecipitations
Transient transfections were performed with Roti-Fect 
(#P001.4, Carl Roth, Karlsruhe, Germany) and maintained 
between 36 and 48 h after transfection. DNA amounts in 
each transfection were kept constant after the addition of an 
empty expression vector. B55α silencing was performed with 
Lipofectamine RNAiMax transfection reagent (#13778100, 
Life Technologies, Carlsbad, USA) according to the manu-
facturer’s instructions. Cells were collected, washed in PBS, 
and lysed in IP buffer [25]. After preclearing the cell lysates 
with protein A/G Sepharose (Santa Cruz), immunoprecipita-
tion was completed on a rotating wheel upon the addition 
of 1 μg of the indicated antibodies and 25 μl of protein A/G 
Sepharose beads. Immunoprecipitated proteins were then 
five times washed in IP buffer and eluted in 2× SDS sample 
buffer, followed by western blotting.
Sample Preparation for LC–MS/MS
Beads used in immunoprecipitation were cleaned three times 
with 500 µl of 200 mM ammonium bicarbonate, and 60 µl 
of 6 M urea/200 mM ammonium bicarbonate were added. 
Samples were then reduced with dithiothreitol (30 nmol, 
37 °C, 60 min), alkylated in the dark with iodoacetamide 
(60 nmol, 25 °C, 30 min), and diluted to 1 M urea with 
200 mM ammonium bicarbonate for trypsin digestion (1 µg, 
37 °C, 8 h, Promega cat # V5113). After digestion, the pep-
tide mix was acidified with formic acid and desalted with 
a MicroSpin C18 column (The Nest Group, Inc) prior to 
LC–MS/MS analysis.
Chromatographic and Mass Spectrometric Analysis
Samples were analyzed using an LTQ-Orbitrap Fusion 
Lumos mass spectrometer (Thermo Fisher Scientific, San 
Jose, CA, USA) coupled to an EASY-nLC 1000 (Thermo 
Fisher Scientific (Proxeon), Odense, Denmark). Peptides 
were loaded directly onto the analytical column and were 
separated by reversed-phase chromatography using a 50-cm 
column with an inner diameter of 75 μm, packed with 2 μm 
C18 particle spectrometer (Thermo Scientific, San Jose, CA, 
USA). Chromatographic gradients started at 95% buffer A 
and 5% buffer B with a flow rate of 300 nl/min for 5 min and 
gradually increased to 25% buffer B and 75% A in 52 min 
and then to 40% buffer B and 60% A in 8 min. After each 
analysis, the column was washed for 10 min with 10% buffer 
A and 90% buffer B. Buffer A: 0.1% formic acid in water. 
Buffer B: 0.1% formic acid in 80% acetonitrile. The mass 
spectrometer was operated in positive ionization mode with 
nanospray voltage set at 2.4 kV and source temperature 
at 275 °C. Ultramark 1621 was used for external calibra-
tion of the FT mass analyzer prior to the analyses, and an 
internal calibration was performed using the background 
polysiloxane ion signal at m/z 445.1200. The acquisition 
was performed in data-dependent acquisition (DDA) mode, 
and full MS scans with 1 micro scan at a resolution of 
120,000 were used over a mass range of m/z 350–1500 with 
detection in the Orbitrap mass analyzer. Auto gain control 
(AGC) was set to 1E5, and charge state filtering disquali-
fying singly charged peptides was activated. In each cycle 
of data-dependent acquisition analysis, following each sur-
vey scan, the most intense ions above a threshold ion count 
of 10,000 were selected for fragmentation. The number of 
selected precursor ions for fragmentation was determined 
by the “Top Speed” acquisition algorithm and a dynamic 
exclusion of 60 s. Fragment ion spectra were produced via 
high-energy collision dissociation (HCD) at a normalized 
collision energy of 28%, and they were acquired in the ion 
trap mass analyzer. AGC was set to 1E4, and an isolation 
window of 1.6 m/z and a maximum injection time of 200 ms 
were used. Digested bovine serum albumin (New England 
Biolabs cat # P8108S) was analyzed between each sample to 
avoid sample carryover and to assure stability of the instru-
ment, and QCloud [26] has been used to control instrument 
longitudinal performance.
LC–MS/MS Data Analysis
Acquired spectra were analyzed using the Proteome Dis-
coverer software suite (v1.4, Thermo Fisher Scientific) and 
the Mascot search engine (v2.6, Matrix Science) [27]. The 
data were searched against a Swiss-Prot human database 
(as in April 2019, 20,421 entries) plus a list [28] of com-
mon contaminants and all the corresponding decoy entries. 
For peptide identification, a precursor ion mass tolerance 
of 7 ppm was used for MS1 level, trypsin was chosen as 
enzyme, and up to three missed cleavages were allowed. 
The fragment ion mass tolerance was set to 0.5 Da for MS2 
spectra. Phosphorylation of serine, threonine and tyrosine, 
oxidation of methionine, and N-terminal protein acetylation 
were used as variable modifications, whereas carbamido-
methylation on cysteines was set as a fixed modification. 
Precursor areas of phosphorylated peptides were extracted 
with the Skyline-daily software (v20.1.1.83); median of the 
area for each condition and fold change was calculated. False 
discovery rate (FDR) in peptide identification was set to a 
maximum of 5%. SAINTexpress algorithm [29] was used to 
score protein–protein interactions.
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GST Pull‑Down Assay
Recombinant GST-PHDs proteins (PHD1, PHD2, and 
PHD3) and GST-HIF were obtained according to standard 
protocols in BL21 bacterial cells and purified using Glu-
tathione-Sepharose 4B (GE Healthcare).
HIF‑1α Hydroxylation Assay
HEK-293T cells were transfected with PHDs as indicated. 
After 24 h of transfection, cells were stimulated as indi-
cated for 24 h. After that, PHDs were immunoprecipitated 
as described [30]. Recombinant human GST-HIF-1α pro-
tein (#ab48734, Abcam) and immunoprecipitated PHDs 
were incubated in the reaction buffer 50 mM Tris/HCl 
(pH 7.5), 1 mM DTT, 50 μM  FeSO4, 5 mM ascorbate, and 
200 µM oxoglutarate for 1 h at 30 °C, respectively. The pro-
lyl hydroxylation reaction was stopped by adding Laemmli 
sample buffer and analyzed by immunoblot assays.
Luciferase Assay
For EPO-Luc transactivation as a marker of HIF stabili-
zation, NIH-3T3-EPO-luc cells, containing three cop-
ies of the HRE consensus sequence from the promoter 
of the erythropoietin gene fused to the luciferase gene, 
were seeded in 96-well plates and incubated with the 
PP2A inhibitors LB-100 (#S7537, Selleckchem, Houston, 
USA) or Okadaic Acid Sodium Salt (#459620 Merk) as 
indicated for 30 min before BAH compound was added. 
Luciferase activity was quantified using Dual-Luciferase 
Assay (#E1483, Promega, Madison, WI, USA) after 6 h 
of stimulation.
qPCR Analysis
STHdhQ7/Q7 and  STHdhQ111/Q111 cells were stimulated 
with BAH for 6 h; after that, mRNA was extracted with 
High Pure RNA Isolation Kit (Roche, Barcelona, Spain). 
For in vivo experiments, total RNA was isolated from mice 
brain tissue using QIAzol lysis reagent and the RNeasy 
Lipid mini kit (#74,804, Qiagen, Hilden, Germany). For 
quantitative reverse transcriptase-PCR assays, total RNA 
(1 µg) was retrotranscribed using the iScript cDNA Syn-
thesis Kit (#1,708,891, Bio-Rad, Hercules, CA, USA) 
and the cDNA was analyzed by real-time PCR using the 
iQTM SYBR Green Supermix (#1708880 Bio-Rad) and 
a CFX96 Real-time PCR Detection System (Bio-Rad). 
Gapdh gene was used to standardize mRNA expression 
in each sample. Gene expression was quantified using the 
 2-ΔΔCt method, and the percentage of relative expression 
against controls (untreated cells or mice) was represented. 
Primer sequences are available upon request.
Striatal Neuroprotection in vitro
STHdhQ7/Q7 and  STHdhQ111/Q111 cells  (104 cells/well) were 
seeded in DMEM supplemented with 10% FBS in 96-well 
plates incubated with increased concentrations of BAH, and 
30 min later, 3-NP at 10 mM (#N5636, Merk) was added. 
Then, 3-NP-induced cytotoxicity was measured by fluores-
cence using the die YOYO-1 (#Y3601, Life Technologies). 
Treated cells were placed in an Incucyte FLR imaging sys-
tem, and the YOYO-1 fluorescence was measured after sev-
eral time points. Object counting analysis is performed using 
the Incucyte FLR software to calculate the total number of 
YOYO-1 fluorescence positive cells and total DNA contain-
ing objects (endpoint). The cytotoxicity index is calculated 
by dividing the number of YOYO-1 fluorescence positive 
objects by the total number of DNA containing objects for 
each treatment group.
Mice Model of Striatal Neurodegeneration
All animal experiments were performed in accordance 
with the European Union guideline and approved by the 
Animal Research Ethics Committee of Cordoba University 
(2014PI/017). Systemic administration of 3-nitropropionic 
acid (3-NP), an inhibitor of the mitochondrial complex II, 
results in a progressive locomotor deterioration and striatal 
degeneration resembling HD in different mice strains [31]. 
Striatal neurodegeneration was induced by seven intraperi-
toneal injections (i.p.) of 3-NP (50 mg/kg) every 12 h in six-
teen-week-old C57BL/6 male (Envigo, Barcelona, Spain). 
Control mice received seven i.p. PBS injections. The treat-
ment was administered daily by i.p. of BAH (30 mg/kg) or 
vehicle (1:1:18 ethanol: cremophor: saline). Twelve hours 
after the last administration of 3-NP, behavioral analyses 
were carried out by measuring hind limb clasping, hind limb 
dystonia, truncal dystonia, and general locomotor activity 
as previously described [32]. Each mouse was given a score 
of 0, 1, or 2 for each test, where 0 corresponds to normal 
behavior and 2 with the maximum motor disorder. Animals 
were sacrificed by cervical dislocation and brains were dis-
sected, one hemisphere was immediately frozen and kept 
at −80 °C for RT-PCR analysis, and the other hemisphere 
was fixed in 4% formaldehyde.
Histological Analysis
Immunohistochemical staining was performed on formalin-
fixed, paraffin-embedded samples. Sections of 5 μm were 
rehydrated in a graded ethanol series. Nissl staining was 
performed using Cresyl-violet (#C5062, Merk); four random 
fields of each brain section were photographed, digitalized 
using a LeicaDFC420c camera, and analyzed using Image J 
software in a blinded manner by two independent observers.
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Immunohistochemistry Analysis
For IHC analysis, brain Sects. (5 µm) were deparaffinized 
and boiled for 10 min in sodium citrate buffer (10 mM, pH 
6.0). Endogenous peroxidase activity was inhibited with 
3.3% hydrogen peroxide in methanol. The sections were 
blocked with blocking reagent (#20773, Merck) and then 
incubated overnight at 4 °C with the following primary anti-
bodies: rabbit anti-Iba-1 (1:100, #019–19741 Wako) and 
mouse anti-NeuN (1:100, #MAB377, Millipore). For block-
ing endogenous mouse IgG and non-specific background, 
rodent block M (#RBM961, Biocare Medical, Concord, CA) 
was used prior anti-NeuN antibody. Slides from anti-Iba-1 
and anti NeuN were incubated with Vectastain Elite ABC 
HRP kit (#416411, Vector Laboratories) followed by sec-
ondary antibody (#21538-M, Merk; #BP-9100–50, Vector 
Laboratories) and were finally visualized with diaminoben-
zidine chromogen (Dako, Santa Clara, CA), photographed 
and digitalized using a Leica DFC420c camera, and ana-
lyzed using Image J software (http:// rsbweb. nih. gov/ ij/).
Confocal Analysis
For antigen retr ieval,  paraff in-embedded brain 
Sects.  (5-μm-thick) were deparaffinized and boiled for 
10 min in sodium citrate buffer (10 mM, pH 6.0). The sec-
tions were washed three times in PBS-triton X100-saponin 
(0.1%). Nonspecific antibody-binding sites were blocked 
for 1 h at room temperature with 3% bovine serum albu-
min (BSA). Next, the sections were incubated overnight at 
4 °C in the following primary antibody diluted in PBS with 
3% BSA: mouse monoclonal anti-GFAP (1:100 dilution, 
#33673, Santa Cruz, Dallas, TX, USA). After extensive 
washing in PBS, slides were incubated with secondary 
antibodies for 1 h at room temperature in the dark. The 
immunoreactions were revealed using anti-mouse Alexa 
488 (1:500 dilution, #A11029, Thermo Fischer Scientific, 
Waltham, MA, USA). Tissue sections were then mounted 
with Vectashield Antifade Mounting Medium with DAPI 
(H-1200, Vector Laboratories, Burlingame, Ca, USA). 
All images were acquired using a spectral confocal laser-
scanning microscope LSM710, (Zeiss, Jena, Germany) 
with a 25 × /0.8 Plan-Apochromat oil immersion lens and 
quantified in 10–15 randomly chosen fields using ImageJ 
software.
Pharmacokinetics
This study was performed by Pharmacology Discovery 
Services Taiwan, Ltd. a company of the Eurofins group. 
The experiment was accepted in accordance with Eurofins 
validation Standard Operating Procedure. Briefly, male SD 
rats (180–250 g. BioLasco Taiwan under Charles River 
Laboratories Licensee) received a single bolus intravenous 
(IV) administration of BAH at 3 mg/kg formulated in 1:1:18 
Ethanol: Cremophor® EL: Saline (0.9% NaCl (Saline; 
Sing-Tong, Taiwan), Cremophor® EL (Sigma, USA), Etha-
nol (Merck, Germany)). Plasma samples and whole brains 
from 3 animals per time point were collected at 0.5, 1, and 
3 h after IV administration, and 3 animals for BAH-free 
plasma and brain were used. Plasma and brain samples were 
processed using acetonitrile precipitation and analyzed by 
LC–MS/MS. The quantitative analysis of plasma and brain 
samples was performed as previously reported [11]. After 
analysis, BAH plasma and brain concentrations versus time 
graph were generated and the brain/plasma ratio per time 
point was calculated.
Statistical Analysis
All the in vitro data are expressed as the mean ± SD, and all 
the in vivo data are expressed as the mean ± SEM. One-way 
ANOVA followed by Tukey’s or Dunnett’s post hoc tests 
was used to determine the statistical significance. The level 
of significance was set at p<0.05. Statistical analyses were 
performed using GraphPad Prism version 6.00 (GraphPad, 
San Diego, CA, USA).
Results
BAH Modifies PHD Activity
To identify the mechanism of action of BAH on the HIF 
pathway, we first analyzed its effect on PHDs activity 
in vitro. PHD recombinant protein hydroxylation activity 
on HIF-1α was determined in the presence or absence of 
BAH. As shown in Fig. 1A and Supplementary Fig. 1A–B, 
BAH did not affect the enzymatic activity of the PHDs in 
vitro. Similar results were obtained for PHD2 performed 
under more restrictive conditions in iron and ascorbic acid 
concentration (Supplementary Fig. 1C). Next, we decided to 
analyze the effect of BAH on the activity of immunoprecipi-
tated PHDs of cells that had been previously stimulated with 
BAH. We found that treatment with BAH produced a clear 
inhibition in the capacity of PHD2 and PHD3 to hydroxy-
late HIF-1α (Fig. 1B; Supplementary Fig. 1E). However, 
no alteration in PHD1 hydroxylation activity was observed 
(Supplementary Fig. 1D). Altogether, these results suggest 
that BAH has the ability to modify PHD2 and PHD3 activ-
ity in an indirect way, without affecting either their binding 
with HIF-1α or through a direct interaction.
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BAH Affects Both Phosphorylation at Ser‑125 
and PHD2 Interactome
Next, we decided to analyze changes in interactome and 
PHD2 post-translational modifications (PTMs) after stimu-
lation with BAH. To do this, PHD2 was immunoprecipi-
tated from cells after stimulation with BAH (Fig. 1C), and 
PTMs and interactome were analyzed by LC–MS/MS. 
The identified peptides allowed a 78% coverture of PHD2 
sequence. From the PTMs identified, a clear difference in 
the levels of Ser-125 phosphorylation was observed after 
treatment with BAH compared to a control situation (Sup-
plementary Fig. 2). Then, and to confirm this observation, 
phosphorylation status was analyzed using a phospho-
specific antibody. Results proved that stimulation with 
BAH produces a 14% reduction in Ser-125 phosphoryla-
tion (Fig. 1D). Previous studies have confirmed that the 
protein phosphatase 2A (PP2A/B55α) is considered one 
of the main modulators of Ser-125 PHD2 phosphorylation 
[13]. To verify whether BAH stimulation modifies Ser-125 
PHD2 phosphorylation via PP2A/B55α dephosphorylation, 
we undertook a loss-of-function approach. B55α depletion 
by siRNA substantially decreased HIF-1α protein level 
after stimulation with BAH (Fig. 1E). In the same way, we 
employed the well characterized PP2A inhibitors LB-100 
and Okadaic Acid (OA). As shown in Fig. 1F, HIF-1α pro-
tein level stimulation mediated by BAH clearly decreased 
after stimulation with LB-100 or OA. Additionally, this 
observation was further reinforced by measuring the down-
stream effects of HIF-1α (EPO induction) in the presence 
of both inhibitors. As shown in Fig. 1G, HIF-1α transcrip-
tional activity mediated by BAH was dose-dependent 
compromised followed by increasing LB-100 and OA 
concentrations.
On the other hand, interactome results revealed that 277 
identified proteins were interacting under normal condi-
tions with PHD2, whereas 232 interactors were found after 
stimulation with BAH (Supplementary Table 1). To elimi-
nate possible non-specific interactors, SAINT algorithm 
was employed with a 0.2 threshold to specifically select 
Fig. 1  BAH alters PHD2 activity modulating Ser-125 Phosphoryla- 
tion. a In vitro hydroxylation reactions were carried out employ- 
ing recombinant GST proteins for HIF-1α and PHD2. Lanes 5th 
and 6th were treated with BAH. Hydroxylation levels of HIF-1α, 
as well as total HIF-1α signals, were analyzed by western blot. b 
HEK-293T cells were transfected with, HA-PHD2 plasmid. After 
24 h, the indicated treatments with BAH or DMOG (PHDs inhibitor, 
positive control) were carried out. A total of 48 h after transfections, 
cell lysates were obtained and PHDs immunoprecipitated with spe-
cific anti-HA antibodies. Finally, these protein fractions were used 
to commit in vitro hydroxylation assays and hydroxylated HIF-1α 
levels were analyzed by immunoblotting. c HEK-293T cells were 
transfected with HA-PHD2 plasmid, treated with 10  μM BAH for 
24 h and finally lysed. PHD2 protein was immunoprecipitated using 
either specific antibody (anti-HA) or an unspecific one (rat IgG), and 
its presence was observed by western blot. We present an Immuno-
precipitation representation of the proteomic analyses performed 
(n = 3). d HEK-293T cells were transfected to express HA-PHD2, 
treated with BAH 50 μM for 24 h and lysed. A fraction was subjected 
to immunoprecipitation (IP) using an anti-HA antibody. After elu-
tion, phosphorylation was revealed with a specific anti-phospho Ser- 
125-PHD2 antibody, while exogenous HA-PHD2 protein levels were 
visualized with an anti-HA antibody by western blotting (top panel). 
The remaining extract fraction was tested for the occurrence of the 
indicated proteins (lower panel). Additionally, images were quanti-
fied (right) using ImageJ software (ImageJ 1.51 k, National Institutes 
of Health USA) and presented in a graph. We show a representative 
blot of three independent experiments. Data represent the mean ± SD 
(n = 3). *p < 0.05. e HEK-293T cells were transfected with B55α or 
scrambled (siControl) siRNAs, after 2  days in culture treated with 
BAH 10 μM for 6 h, and B55α and HIF-1α protein expression was 
analyzed by immunoblotting (representative blot of three independent 
experiments performed). Images were quantified (low) using ImageJ 
software, and HIF-1α and B55α protein levels were presented in a 
graph. Data represent the mean ± SD (n = 3). *p < 0.05. f HEK-293T 
cells were pretreated with PP2A inhibitors LB-100 (5 nM) and Oka-
daic Acid (5 nM) for 30 min. Then, treated with 10 μM BAH for 6 h 
and finally lysed. HIF-1α protein was detected using a specific anti-
body. We present a representative western blot of three independent 
analyses performed (n = 3). g NIH-3T3 fibroblasts stably transfected 
with a luciferase-HRE (NIH3T3-EPO-luc) were stimulated with the 
indicated concentrations of BAH, LB-100, and Okadaic Acid. Data 
represent the mean ± SD (n = 3). *p < 0.05, **p < 0.01
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those proteins that are not present in an antibody immuno-
precipitation control (IgG). After that restriction, the pro-
teins obtained under control conditions were reduced to 28, 
whereas those found following treatment with BAH were 
23 (Fig. 2A; Supplementary Table 2). Further treatment of 
the data enabled us to categorize these identified proteins 
into three different groups. The first group was character-
ized by those proteins present only in the untreated cells, 
which are consequently lost following treatment with BAH 
(28.12% of identified proteins). The second group was 
formed by those proteins that remained unaltered within 
the treatments (58.38%). Finally, the last group contained 
the proteins that appeared only after treatment with BAH 
(12.5%) (Fig. 2A). The subsequent functional characteriza-
tion of these data through an over-representation analysis 
has allowed us to have a global vision of the contribution of 
the alteration of PHD2 interactome mediated by the stimu-
lation with BAH on different cell functions, amongst which 
we can mention a clear reduction in pathways related to 
co-translational protein targeting to membrane, translation 
initiation or cell adhesion molecule binding (Fig. 2C).
Effects of BAH on Striatal Neurons Expressing 
Normal and Mutated Huntingtin
To study the effect of BAH on the HIF pathway, immortal-
ized striatal neurons expressing normal huntingtin protein 
 (STHdhQ7/Q7) or a mutant version associated with juvenile-
onset of HD  (STHdhQ111/Q111) [24] were stimulated with 
the indicated doses and protein expression of HIF-1α and 
PHDs were analyzed. As depicted in Fig. 3A, BAH stabi-
lized HIF-1α protein in a concentration-dependent manner in 
neurons expressing normal and mutated huntingtin proteins. 
Although the basal expression of PHDs proteins is higher in 
 STHdhQ111/Q111 cell line compared to  STHdhQ7/Q7, no sig-
nificant changes were found after treatment with BAH. To 
further investigate the activation of the HIF pathway, vascu-
lar endothelial growth factor (Vegf) and B cell leukemia/lym-
phoma 2 (Bcl-2)/adenovirus (E1B)-19KD-interacting pro-
tein 3 (Bnip3) gene expression was determined (Fig. 3B–C). 
In both cases, BAH was able to induce the expression of Vegf 
and Bnip3 in a concentration-dependent manner. Finally, the 
neuroprotective effect of BAH was evaluated in response to 
Fig. 2  BAH affects PHD2 interactome. a Significative data of the 
interactome analyses performed: Graph bar shows the protein number 
of each group. b Venn diagram classifies the obtained proteins using 
MSigDb categories and individual interactors for control and BAH. 
c Plot TOP 5 over-represented pathways per category and treatment 
where labels indicate the number of overlapping genes in a given 
functional category and the length of the bar the significance of the 
enrichment. The dashed line indicates the consensus cutoff of p = 0.05
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mitochondrial dysfunction in neurons induced by the selec-
tive complex II inhibitor 3-nitropropionic acid (3-NP). As 
expected, 3-NP was strongly cytotoxic in  STHdhQ111/Q111 
cells compared to  STHdhQ7/Q7 cells, and treatment with 
BAH protected both types of cells from 3-NP-induced cell 
death (Fig. 3D–E).
Neuroprotective Effect of BAH in a Murine Model 
of Neuronal Striatal Degeneration
In order to confirm the neuroprotective action of BAH 
in vivo, a model of Huntington’s disease based on 3-NP 
administration was used (Fig. 4A). Treatment with 3-NP 
results in several alterations, including neurological and 
histological changes characteristic of some aspects of HD 
pathology. Compared to control animals treated with vehi-
cle, the 3-NP-treated mice exhibited high scores in hind 
limb clasping, locomotor activity, hind limb dystonia, and 
kyphosis (Fig. 4B) which were improved after the treat-
ment with BAH. We next investigated the impact of BAH 
in striatal degeneration and atrophy. The administration of 
3-NP reduced the number of neurons in the striatum, as 
determined by Nissl staining and NeuN immunohistochem-
istry (Fig. 4C–D). In addition, BAH-mediated neuropro-
tection was associated with reduced 3-NP-induced astro-
gliosis as determined by GFAP immunofluorescence and a 
decrease in the activated microglia. 3-NP mice showed the 
associated change of morphology typical of microglial acti-
vation with the cytoplasmatic ramifications retracted and 
an ameboid appearance [33] whereas Iba1-immunopositive 
cells from control mice and those treated with BAH exhib-
ited a ramified morphology with extensive branching and 
processes.
We also analyzed the expression of specific pro-inflammatory 
markers. In 3-NP-lesioned mice, upregulation of mRNA levels 
of inflammatory markers such as Cox-2, iNos, Il-1, and Il-6 was 
observed and fully inhibited by treatment with BAH (Fig. 5). In 
addition, other genes related to oxidative stress and neuropro-
tection were studied. Bdnf and Sod1 genes which are associated 
with neuroprotection [34] were enhanced in mice treated with 
BAH, whereas others such as Nqo1, Ucp-2, and p21 had their 
expression increased in 3-NP-lesioned mice but almost recov-
ered their basal levels after the treatment with the compound 
BAH.
Fig. 3  Effects of compound BAH on striatal cells harboring wild type 
and mutant huntingtin. a  STHdhQ7/Q7 and  STHdhQ111/Q111 cells were 
treated with BAH for 6  h and further analyzed for HIF-1α, PHD1, 
PHD2, and PHD3 expression by immunoblot. The mRNA expres-
sion levels of Vegf-A b and Bnip3 c genes were quantified by qPCR 
in  STHdhQ7/Q7 and  STHdhQ111/Q111 cells after 6  h of treatment with 
the compound. Data represent the mean ± SD (n = 3). *p < 0.05, 
**p < 0.01, BAH-treated cells vs untreated cells (one-way ANOVA 
followed Dunnett’s test). d  STHdhQ7/Q7 and  STHdhQ111/Q111 cells 
were pre-incubated with the indicated concentrations of BAH for 6 h 
and stimulated with 3-NP for 30 h. The percentage of neuronal death 
was determined by YOYO-1 and referred to vehicle-treated neurons. 
Data represent the mean ± SD (n = 3). *p < 0.05, ***p < 0.001 3-NP 
treated cells vs untreated cells; #p < 0.05, ###p < 0.001 3-NP + BAH-
treated cells vs 3-NP treated cells (two-way ANOVA followed Tuk-
ey’s test)
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As BAH exerted a neuroprotective action in vivo, we 
evaluated its brain penetration. Pharmacokinetic analyses 
were performed in rats after administration of BAH (2 mg/
kg). The highest plasmatic levels for BAH were detected 
after 30 min and then rapidly declined at 120 min indicating 
a rapid excretion. Importantly, the levels of BAH in the brain 
were similar to those in the plasma, indicating a very good 
brain penetration and not accumulative effect was found at 
the time point studied (Fig. 6).
Discussion
Neurodegenerative diseases such as HD are characterized 
by a progressive deterioration in the structure and function 
of the brain. Its incidence has raised significantly mainly 
because of the increase in life expectancy, representing a 
major health problem that demands new therapeutic strat-
egies for their treatment. Accumulating data indicate that 
mild HIF-1α activation (hypoxia preconditioning) protects 
the brain [35] against several types of injury such as ROS 
[36] and inflammation [37] through the induction of adap-
tive mechanisms that involve the modulation of glucose 
transporters, glycolytic enzymes, and angiogenic factors. 
Moreover, HIF-1α-mediated upregulation of Bnip3 has 
been shown to mediate neuroprotection by activating the 
autophagy pathway [38].
Our results suggest that BAH has the ability to modify 
PHD2 activity without affecting either their binding with 
HIF-1α or through a direct interaction. The PHD2 Ser-
125 phosphorylation clear reduction obtained in MS/MS, 
added to its validation using a phospho-specific Ser-125-
PHD2 antibody, indicates that BAH reduces this residue 
phosphorylation. In this sense, it has been previously 
described that Ser-125 phosphorylation increases PHD2 
activity leading to a higher HIF-1α degradation. Moreo-
ver, this phosphorylation status is accurately controlled by 
the P70S6K kinase and PP2A phosphatase [13]. Although 
further studies should be done to clarify how BAH modi-
fies PHD2 phosphorylation status, we found that pan-
PP2A inhibitors LB-100 and OA inhibited BAH-induced 
HIF-1α stabilization. PP2A-activating drugs (PADs) are 
being actively sought and investigated not only as poten-
tial anti-cancer treatments but also against inflammatory 
and neurodegenerative diseases [39]. PP2A is a highly 
complex heterotrimeric enzyme that catalyzes the selec-
tive removal of phosphate groups from protein serine and 
threonine residues and further experiments are warranted 
to identify the PP2A subtype involved in the mechanism 
of action for BAH.
Fig. 4  Compound BAH is neuroprotective in 3-NP-intoxicated mice. 
a  Representative scheme of the experimental protocol used for the 
induction of HD in mice. b The behavioral score was determined 
12 h after 3-NP intoxication. Mice were treated with BAH (30 mg/
kg) as indicated. Hind limb clasping, general locomotor activity, hind 
limb dystonia, and kyphosis were rated from 0 to 2 based on sever-
ity, with score 0 indicating normal function, and 2 indicating the 
most severe affected function. Values are expressed as means ± SEM 
(n = 6). ***p < 0.001 3-NP vs. Vehicle; #p < 0.05, ###p < 0.001 
3-NP + BAH vs 3-NP (one-way ANOVA followed Tukey’s test). c 
Nissl staining, NeuN, and Iba-1 immunohistochemistry and immuno-
fluorescence labeling of GFAP (green fluorescence) in coronal striatal 
brain sections from the different mice groups. d Quantifications of 
Nissl, NeuN, Iba1, and GFAP expression (yellow arrows) were per-
formed with Image J software. Values are expressed as mean ± SEM 
(n = 6). ***p < 0.001 3-NP vs. Vehicle; ###p < 0.001 3-NP + BAH vs 
3-NP (one-way ANOVA followed Tukey’s test)
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Fig. 5  Treatment with BAH induces changes in gene expression. 
Gene expression of inflammatory markers including Il-6, iNos, Cox-
2, and Il-1β was significantly downregulated in 3-NP + BAH-treated 
mice compared with 3-NP mice, whereas Bdnf and Sod1 expression 
was the opposite. Neuroprotection markers such as Nqo1, Ucp-2, 
and p21 also altered their expression after 3-NP insult. Values are 
expressed as means ± SEM (n = 6 animals per group). **p < 0.01, 
***p < 0.001 3-NP vs. Vehicle; #p < 0.05, ##p < 0.01, ###p < 0.001 
3-NP + BAH vs 3-NP (one-way ANOVA followed Tukey’s test)
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HIF-1α also upregulates a plethora of genes including 
vascular endothelial growth factor (VEGF) and erythropoi-
etin, both showing neuroprotective activity in different ani-
mal models of neurological diseases. Although high levels of 
VEGF are found significantly increased in HD patients when 
compared with the controls [40], and there is evidence that 
VEGF causes BBB disruption [40, 41], other reports indicate 
that VEGF itself has neurotrophic effects, as it stimulates 
axonal outgrowth and increases the survival of neurons at 
different regions of the brain [42], and also rescues hip-
pocampal cells from death induced by serum withdrawal 
[43]. In addition, HIF PHD inhibition also protects cortical 
neurons from 3-NP-induced cytotoxicity that correlates with 
enhanced VEGF expression [20]. Furthermore, low doses of 
VEGF165 are neuroprotective in in vitro and in vivo models 
of HD caused by overexpression of mutated huntingtin [44].
Betulinic acid (BA) is a pleiotropic bioactive compound 
that has been described to act on different molecular tar-
gets that mediated neuroprotection and antiinflammatory 
activity. It is likely that distinct pharmacophores in the BA 
molecule are responsible for the activity on different tar-
gets and therefore BAH would retain some of the activities 
attributed to BA. Thus, one of the possible mechanisms 
from which BAH could carry out its actions would be 
decreasing the inflammatory response. A number of stud-
ies indicate that activation of the immune system and an 
altered immune response are evident even in the premani-
fest stage of Huntington’s disease [45]. In fact, activated 
microglia and reactive astrocytes contribute to neural 
death in HD pathology [46]. Immunohistochemical analy-
sis of the striatum from mice treated with 3-NP showed 
that BAH treatment reduced the expression of GFAP, the 
main biomarker of reactive astrogliosis [47]. In addition, 
activated microglia, which is clearly present in intoxicated 
3-NP mice, turned into a resting state when treated with 
BAH compound. These results are in accordance with the 
decrease of the expression of proinflammatory cytokines 
(Il-1β, Il-6, iNos, and Cox-2) observed by RT-PCR, sug-
gesting that BAH would be able to reduce the cascade of 
proinflammatory cytokines induced by activated microglia 
and astrogliosis [48]. In addition, we also investigated the 
expression levels of the brain-derived neurotrophic factor 
(Bdnf), a critical survival factor for striatal neurons that 
die in HD [49]. Results showed a slight decrease in its 
level after 3-NP administration, as previously described 
[50], but a significant increase in mice treated with BAH 
compound, suggesting other mechanism by which BAH 
could induce neuroprotection.
Finally, oxidative stress and mitochondrial dysfunction 
have been linked to neurodegenerative disorders including 
HD [51, 52]. Previous reports indicated that HIF PHDs 
inhibitors protected striatal cells bearing a mutated form 
of the huntingtin protein against mitochondrial toxin-
induced cytotoxicity [20]. Our results corroborate these 
publications, showing a remarkable protection from 3-NP 
in  STHdhQ111/Q111 cells treated with BAH since the low-
est concentration (1 μM). In the mice model, HIF-1α-
dependent genes involved in responses to stress with neu-
roprotective actions were studied. Nqo1, p21, and Ucp-2 
gene expressions were increased in those mice treated with 
3-NP, indicating a stress situation. However, a decrease in 
the level of these genes after BAH treatment prompted us 
to believe that our compound produced neuroprotective 
actions.
In summary, the hypoximimetic triterpenoid derivative 
BAH was able to alter the response pathway to hypoxia 
through the decrease of PHD2 phosphorylation levels. In 
addition, the compound provided neuroprotection in a stri-
atal degeneration mice model induced by 3-NP, improving 
the clinical symptoms and antioxidant defenses in the brain, 
preventing neuronal loss, decreasing reactive astrogliosis 
and microglial activation, and decreasing the expression of 
proinflammatory markers. These results indicated that BAH 
has the potential for further pharmacological development of 
a novel drug candidate for the treatment of HD and perhaps 
other neurodegenerative diseases.
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